Dr. Sinha is the Chief Scientific Officer of BridgeBio Pharma. She has extensive experience in discovery and preclinical development of small molecules involved in the pathogenesis of hematologic, cardiovascular and inflammatory diseases. Previously, she served as Prior to joining BridgeBio, she was the Chief Scientific Officer of Global Blood Therapeutics, and before that, Vice President, Head of Biology at Portola Pharmaceuticals, as well as senior research positions at Millennium Pharmaceuticals and COR Therapeutics. She has been directly involved in the discovery or development of GBT440, Bevyxxa®, and AndexXa®. Dr. Sinha received her Ph.D. in biochemistry from the University of Georgia and her B Sc. with honors in chemistry from Presidency College.